ArticleThe Journal of antibiotics2025
Gold nanoparticles functionalised with vancomycin enhance antibacterial activity and inhibit Streptococcus pneumoniae adherence and invasion in alveolar cells.
Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Antimicrobial Strategies in the Era of Resistance: It Is Too Early to Give Up Antibiotic Therapy.International journal of molecular sciences · 2026Review
- Nanotechnology-Enabled Strategies to Overcome Antibiotic Resistance in Respiratory Infections: Mechanisms, Platforms, and Translational Challenges.Biomedicines · 2026Review
- Vancomycin-Mediated Binding of DNA Origami Nanostructures to Gram-Positive and Gram-Negative Bacteria.Chembiochem : a European journal of chemical biology · 2026Article
- Where and when to strike: Spatiotemporally controlled smart nanomedicines for precision antibacterial therapy.Acta pharmaceutica Sinica. B · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Streptococcus pneumoniae (S. pneumoniae) is a leading cause of respiratory infections, with increasing antibiotic resistance posing a major challenge. While gold nanoparticles (AuNPs) functionalised with antibiotics have been explored, their impact on bacterial adherence and invasion remains underexplored. This study presents a vancomycin-conjugated AuNP formulation designed to enhance antibacterial efficacy and prevent S. pneumoniae colonisation. The nano-formulation was characterised using UV-Vis spectroscopy and TEM, confirming successful conjugation and a uniform spherical size of 23 ± 1 nm. Minimum inhibitory concentration (MIC) assays demonstrated a significant reduction in the required concentrations of AuNPs (from 512 to 32 µg ml
Indexed as
Identifiers
40817314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.